Biomerica, Inc. (BMRA)
| Previous Close | 0.9100 |
| Open | 0.8800 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.8800 - 0.9200 |
| 52 Week Range | 0.7000 - 4.0400 |
| Volume | |
| Avg. Volume | 54,126 |
| Market Cap | 14.899M |
| Beta (5Y Monthly) | -0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4100 |
| Earnings Date | Jan 11, 2024 - Jan 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireBiomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16
IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings. About Biomerica (NASDAQ:
- GlobeNewswire
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National Accounts hired along with first set of regional sales representatives IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using
- GlobeNewswire
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes pre-launch phase for inFoods IBS; veteran Vice President of sales and nation
